Junxiao Wang 2025 Joint Meeting of the COSA ASM and IPOS Congress

Abstracts this author is presenting:

• Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials — Afternoon tea, Poster session 1 & Exhibition
• Comparison of T-DM1 and Trastuzumab-Pertuzumab in HER2-Positive Breast Cancer Patients with Residual Disease After Neoadjuvant Therapy: A Retrospective Study — Afternoon tea, Poster session 1 & Exhibition